Key Details
Price
$3.06Annual ROE
-68.22%Beta
0.24Events Calendar
Next earnings date:
May 14, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 30, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jan 02, 2024Analyst ratings
Recent major analysts updates
Screeners with KTTA included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing
Pasithea Tx appoints Dr. Rebecca Brown, an expert in Neurofibromatosis and Director at Mount Sinai, to its Scientific Advisory Board to aid in PAS-004.
Pasithea Therapeutics (NASDAQ: KTTA ) stock is falling on Wednesday after the company's shares experienced major volatility on Tuesday. Investors watching KTTA stock will note that it closed out Tuesday up less than 1%.
-- Attendees may request 1 x 1 meeting with management at [email protected] -- PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13.
FAQ
- What is the primary business of Pasithea Therapeutics?
- What is the ticker symbol for Pasithea Therapeutics?
- Does Pasithea Therapeutics pay dividends?
- What sector is Pasithea Therapeutics in?
- What industry is Pasithea Therapeutics in?
- What country is Pasithea Therapeutics based in?
- When did Pasithea Therapeutics go public?
- Is Pasithea Therapeutics in the S&P 500?
- Is Pasithea Therapeutics in the NASDAQ 100?
- Is Pasithea Therapeutics in the Dow Jones?
- When was Pasithea Therapeutics's last earnings report?
- When does Pasithea Therapeutics report earnings?
- Should I buy Pasithea Therapeutics stock now?